2020 Webinar: Prevention and Management of Ascites in Cirrhosis: Controversies and New Approaches
Recorded On: 03/10/2020
This webinar will review recent important advances in understanding of how to care for patients with cirrhosis and ascites. Specifically, it will discuss how to risk stratify patients for ascites and new strategies for ascites prevention. In addition, it will address evidence-based approaches to the management of ascites among patients who have chronic kidney disease, a challenging and common clinical scenario. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.
Scott W. Biggins (Moderator)
Dr. Scott W. Biggins is Chief of Hepatology, Director of the Liver Care Line for UW Medicine, and Director of the Center for Liver Investigation Fostering Discovery (C-LIFE) at the University of Washington. Dr. Biggins is a national recognized clinician and researcher in the field of Hepatology. He received his undergraduate degree in chemical engineering (bioengineering option) from the University of California, Los Angeles (1994) and his medical degree from the University of Southern California (1999). He completed a residency in Internal Medicine at Oregon Health & Science University (2002) and his Gastroenterology fellowship training at the University of California, San Francisco (2005). He was also awarded a Master’s degree in Clinical Research from the University of California, San Francisco (2006).
Dr. Biggins' clinical interests are the risk reduction and management of complications of end-stage liver disease, and the clinical evaluation and care of liver transplant candidates and recipients. He has been recognized as a fellow of American Association for the Study of Liver Diseases (FAASLD), American Society of Transplantation (FAST), and American Gastroenterological Association (AGAF). He is Vice Chair of the AASLD Special Interest Group (SIG) for Portal Hypertension.
His research is focused on complications of portal hypertension, improving recipient and donor selection for liver transplantation and revising organ allocation algorithms in order to maximize patient outcomes. He has received research funding from the American Liver Foundation, National Institutes of Health and the Agency for Healthcare Research and Quality. He has published more than 75 papers in peer-reviewed journals including the New England Journal of Medicine, Gastroenterology, HEPATOLOGY, and Liver Transplantation.
Elizabeth Verna (Moderator)
Dr. Elizabeth Verna is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist.
In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.
Juan G. Abraldes
Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004). He was a faculty member of the Liver Unit, at Hospital Clinic Barcelona, until 2013, when he moved to the University of Alberta.
He has published more than 200 papers on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis and was the chair of the AASLD Special Interest Group in Portal Hypertension between 2017 and 2018.
Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 28 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research, Canadian Liver Foundation and the National Institutes of Health.
She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, she also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. Recently, she served as the Chair of the "Acute-on-Chronic Liver Failure Special Interest Group" of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology.
She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She is currently on the writing committee to write the guidelines for the management of refractory ascites for the American Association for the Study of the Liver. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.